Vaccinia virus strain LC16m8 defective in the B5R gene keeps strong protection comparable to its parental strain Lister in immunodeficient mice

Vaccine. 2015 Nov 9;33(45):6112-9. doi: 10.1016/j.vaccine.2015.07.076. Epub 2015 Aug 1.

Abstract

Background: Attenuated vaccinia virus strain, LC16m8, defective in the B5R envelope protein gene, is used as a stockpile smallpox vaccine strain in Japan against bioterrorism: the defect in the B5R gene mainly contributes to its highly attenuated properties.

Methods: The protective activity of LC16m8 vaccine against challenge with a lethal dose of vaccinia Western Reserve strain was assessed in wild-type and immunodeficient mice lacking CD4, MHC class I, MHC class II or MHC class I and II antigens.

Results: The immunization with LC16m8 induced strong protective activity comparable to that of its parent strain, Lister (Elstree) strain, in wild-type mice from 2 days to 1 year after vaccination, as well as in immunodeficient mice at 2 or 3 weeks after vaccination. These results implicated that the defect in the B5R gene hardly affected the potential activity of LC16m8 to induce innate, cell-mediated and humoral immunity, and that LC16m8 could be effective in immunodeficient patients.

Conclusion: LC16m8 with truncated B5 protein has an activity to induce immunity, such as innate immunity and subsequent cell-mediated and humoral immunity almost completely comparable to the activity of its parental strain Lister.

Keywords: Bioterrorism; Efficacy evaluation study; Immunodeficient subject; LC16m8; Smallpox vaccine; WHO stockpile vaccine.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Viral / blood
  • Bioterrorism
  • Immunocompromised Host*
  • Japan
  • Membrane Glycoproteins / genetics*
  • Mice
  • Smallpox / immunology*
  • Smallpox / prevention & control
  • Smallpox / virology
  • Smallpox Vaccine / administration & dosage
  • Smallpox Vaccine / immunology
  • Strategic Stockpile
  • Vaccines, Attenuated / administration & dosage
  • Vaccines, Attenuated / immunology
  • Vaccinia virus / genetics*
  • Vaccinia virus / immunology*
  • Viral Envelope Proteins / genetics*

Substances

  • Antibodies, Viral
  • Membrane Glycoproteins
  • Smallpox Vaccine
  • Vaccines, Attenuated
  • Viral Envelope Proteins
  • 42kDa protein, Vaccinia virus